An electrochemical immunosensor for anti-T. cruzi IgM antibodies, a biomarker for congenital Chagas disease, using a screen-printed electrode modified with gold nanoparticles and functionalized with shed acute phase antigen

Regiart, Matías; Pereira, Sirley V.; Bertolino, Franco A.; Garcı́a, Carlos D.; Raba, Julio; Aranda, Pedro R.

doi:10.1007/s00604-016-1752-4

Cited by 18 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, anti-SAPA antibodies (IgM or IgG) have been detected in 90% of acute chagasic patients and in 7-10% of chronic patients [81]. This biosensor can distinguish between congenitally infected and non-infected infants when cord blood is tested, the sensitivity is in the ng/mL range (3.03 ng/mL) and the linear response between 10 and 200 ng/mL [80]. This device could facilitate and speed up the unequivocal diagnosis of congenital transmission, since it does not depend on the detection of parasite in newborns or the clearance of maternal antibodies in infants.…”

Section: Biosensorsmentioning

confidence: 96%

“…More recently, a similar approach was used to develop a biosensor to detect and quantify anti-T. cruzi IgM antibodies in newborns and infants and to predict congenital CD [80]. In this case, a SAPA (shed acute-phase antigen) was immobilized in a SPCE together with AuNPs.…”

Section: Biosensorsmentioning

confidence: 99%

“…In 2016, the same group tested SPRCruzi with a higher number of positive and negative serum samples and compared their results with conventional serological tests. SPRCruzi showed 100% sensitivity (cutoff ΔθSPR 17.2°), 99.6% global accuracy, and a better specificity (97.2%) compared to ELISA [80]. Nonetheless, the use of this device is still limited to laboratories since expensive and heavy SPR equipment is required.…”

Section: Biosensorsmentioning

confidence: 99%

See 2 more Smart Citations

Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities

2019

View full text Add to dashboard Cite

Chagas disease (CD), caused by Trypanosoma cruzi, affects millions of people worldwide. Although CD R&D has made progress during the last decade, clinicians and general practitioners are still facing the same challenge, i.e., the lack of adequate markers of clinical cure, hindering assessment of new drug efficacy in clinical trials and counseling of patients about treatment outcome. To date, no new markers have been validated as surrogates of seroreversion-the only marker of parasitological cure which is itself considered to be a surrogate of clinical benefit. T. cruzi DNA detected using PCR cannot currently be considered as a surrogate of seroconversion. Much emphasis has been placed on different T. cruzi antigens but no definite proof of correlation between titers, as determined by serology at a given timepoint, and seroreversion has been shown. Thanks to the improvement of analytical methods and the application of new methodologies, the identification of potential new markers is being facilitated, and some of these are progressing. However, there is a long journey from the identification of a potential biomarker to its clinical validation and acceptance by the regulatory authorities that requires a common effort from the entire Chagas community.

show abstract

Section: Biosensorsmentioning

confidence: 96%

Section: Biosensorsmentioning

confidence: 99%

Section: Biosensorsmentioning

confidence: 99%

See 1 more Smart Citation

Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities

2019

View full text Add to dashboard Cite

show abstract

“…Recently, a sandwich immunosensor for anti‐IgM T. cruzi ‐specific antibodies, which are a biomarker for congenital Chagas disease was also reported. AuNPs/SPCEs functionalized with recombinant shed acute phase antigen were used, AuNPs providing an increased active surface area, high conductivity and improved electrocatalytic activity …”

Section: Tropical Diseasesmentioning

confidence: 99%

Electrochemical Biosensing for the Diagnosis of Viral Infections and Tropical Diseases

2017

View full text Add to dashboard Cite

Rapid and reliable diagnosis of viral infections and tropical diseases and timely initiation of appropriate treatment are essential for their successful clinical management. This Review summarizes some basic concepts regarding the main viral infection and tropical diseases to which society is facing today and the conventional methods available for their detection. The tremendous potential offered by electrochemical affinity biosensors to address this important challenge, meeting the required demands for viral infections and tropical diseases diagnosis, is clearly stated by discussing challenges, opportunities, implementation, and application of selected examples focused on the determination of specific biomarkers of different molecular (genetic, regulatory, and functional) levels. The highlighted approaches demonstrate the use of a plethora of specific receptors and assay formats and a great diversity of attractive electrochemical approaches in this rapidly advancing and highly interesting field.

show abstract

“…73,76 More recent electrochemical immunosensors with nanoscale gold particles as transducers are able to detect target CD proteins with an LOD ~ 20 pM. 77 In comparison, the presented InP NW biosensor surpasses the detection limit of the existing diagnosis methods ~1000-fold, which may allow the detection of chronical Chagas infection more reliably, overcoming the limitation of the antibody titer in the human blood serum, which is usually very low in such cases. 44,45 Since IBMP8-1 is a chimeric T. cruzi protein developed for diagnostic purposes using ELISA assays, we have carried out Surface Plasmon Resonance (SPR) measurements to compare biosensor antigen:antibody interaction sensing capabilities ( Figure S6, Table S3).…”

mentioning

confidence: 97%

InP Nanowire Biosensor with Tailored Biofunctionalization: Ultrasensitive and Highly Selective Disease Biomarker Detection

et al. 2017

View full text Add to dashboard Cite

Electrically active field-effect transistors (FET) based biosensors are of paramount importance in life science applications, as they offer direct, fast, and highly sensitive label-free detection capabilities of several biomolecules of specific interest. In this work, we report a detailed investigation on surface functionalization and covalent immobilization of biomarkers using biocompatible ethanolamine and poly(ethylene glycol) derivate coatings, as compared to the conventional approaches using silica monoliths, in order to substantially increase both the sensitivity and molecular selectivity of nanowire-based FET biosensor platforms. Quantitative fluorescence, atomic and Kelvin probe force microscopy allowed detailed investigation of the homogeneity and density of immobilized biomarkers on different biofunctionalized surfaces. Significantly enhanced binding specificity, biomarker density, and target biomolecule capture efficiency were thus achieved for DNA as well as for proteins from pathogens. This optimized functionalization methodology was applied to InP nanowires that due to their low surface recombination rates were used as new active transducers for biosensors. The developed devices provide ultrahigh label-free detection sensitivities ∼1 fM for specific DNA sequences, measured via the net change in device electrical resistance. Similar levels of ultrasensitive detection of ∼6 fM were achieved for a Chagas Disease protein marker (IBMP8-1). The developed InP nanowire biosensor provides thus a qualified tool for detection of the chronic infection stage of this disease, leading to improved diagnosis and control of spread. These methodological developments are expected to substantially enhance the chemical robustness, diagnostic reliability, detection sensitivity, and biomarker selectivity for current and future biosensing devices.

show abstract

An electrochemical immunosensor for anti-T. cruzi IgM antibodies, a biomarker for congenital Chagas disease, using a screen-printed electrode modified with gold nanoparticles and functionalized with shed acute phase antigen

Cited by 18 publications

References 24 publications

Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities

Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities

Electrochemical Biosensing for the Diagnosis of Viral Infections and Tropical Diseases

InP Nanowire Biosensor with Tailored Biofunctionalization: Ultrasensitive and Highly Selective Disease Biomarker Detection

Contact Info

Product

Resources

About